As a patient, you probably see lots of hype-filled reports about various drugs. After a drug is approved, there’s an inevitable blitz of negative publicity which often scares people away from important new solutions that could help them.
There has been so much news lately about Multaq (dronedarone), the drug designed to provide the benefits of amiodarone but with fewer risks. This drug is important to people with afib, especially those with heart disease whose choices are limited, so it’s time to put into context for patients what has transpired in the two years since FDA approval.
These two companion articles provide an in-depth analysis into issues that have been reported about Multaq, including whether it can cause:
- Worsened heart failure
- Irregular heartbeats, including potentially lethal ones
- Impaired kidney function
- Liver damage
- Drug interactions, including with Pradaxa (dabigatran)
These articles also examine the implications of the recently suspended PALLAS clinical trial for patients with permanent atrial fibrillation as well as when Multaq should be given. And finally, they explore the latest good news about Multaq.
If you have afib, you need to read these two articles, and please spread the word to others with afib as well.
*This blog post was originally published at Atrial Fibrillation Blog*